Skeletal Muscle Loss Under Chemotherapy And Its Association With Survival And Systemic Treatment Toxicity In Metastatic Colorectal Cancer: An Ageo Prospective Multicenter Study.

To our knowledge, this is the first study to assess prospectively the association of skeletal muscle loss with survival and treatment toxicities in non-pretreated patients with mCRC. Pretherapeutic sarcopenia was not associated with poor outcomes, but the loss of skeletal muscle mass within 60 days from treatment start was highly prognostic, independently of other prognostic and nutritional factors.